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LETTER TO THE EDITOR
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Pulmonary arterial hypertension (PAH) is 
a severe, progressive life-threatening condition. 
Inter-atrial shunt creation can lead to cardiac 
output increment at the expense of arterial blood 
desaturation [1, 2]. At long-term follow-up, how-
ever, spontaneous defect closure can occur [3, 4]. 
Lately, novel implantable atrial communication 
devices have been introduced, which may become 
a treatment option in end-stage PAH patients [5–7]. 
Atrial flow regulator (AFR) device delivered by 
Occlutech company is currently under European 
Community registration for compassionate use in 
patients with severe right ventricular (RV) failure 
due to pulmonary hypertension or left heart failure 
and under United States Food and Drug Adminis-
tration’s (FDA) emergency use guidance. 
The present study describes the first AFR 
implantation in Poland in a 28-year-old male with 
drug resistant severe PAH, which developed 20 
years subsequent to total correction of a congeni-
tal heart defect (double outlet right ventricle with 
ventricular septal defect) performed at the age 
of two. Cardiac magnetic resonance revealed no 
residual intracardiac shunt. No signs of PAH were 
evident until 2012 (age 22), when PAH-specific 
drug therapy was started. Since 2016 progressive 
deterioration started with one syncopal episode 
during exercise. Since March 2018 RV failure 
(World Health Organization [WHO] functional class 
IVa) with fluid retention (and up to 10 kg weight 
gain) had developed. The patient was on a waiting 
list for lung transplantation. In view of no other 
clinically meaningful treatment alternative, a deci-
sion to implant the AFR was made. Approval of the 
local ethics committee and informed consent from 
the patient was obtained. The patients’ weight was 
71 kg, height 172 cm, body surface area 1.85 m2, 
blood pressure 110/80 mmHg, oxygen saturation 
(SpO2) 94%, heart rate (sinus rhythm) 100 bpm. 
He had mild liver enlargement, as well as mild 
leg and abdominal edema. Right heart catheter-
ization confirmed severe PAH with equalization 
of pulmonary and systemic pressure. The proce-
dure was performed under general anesthesia, 
induced with etomidate, fentanyl and rocuronium 
for muscle relaxation and was maintained using 
volatile sevoflurane (0.7 to 1.1% administered in 
air/oxygen mixture). Muscle relaxation was re-
versed with sugammadex. Trans-septal puncture 
was performed under three-dimensional transo-
esophageal echocardiography guidance (Suppl. 
Video 1). Static septostomy was performed, fol-
lowed by progressive balloon dilatation of atrial 
septum (balloon size 10–12 mm). Extra stiff wire 
was located in the left upper pulmonary vein. 
The AFR device (5 mm height/6 mm fenestration 
diameter) was inserted using 10 F introducing 
system and stabilized without complications. The 
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AFR is a self-expandable double-disc nitinol wire 
mesh construction dedicated to create inter-atrial 
communication and allow blood flow across the 
interatrial septum (Fig. 1). The disc diameter 
ranges from 16 to 23 mm, fenestration from 4 to 
10 mm, and connective waist between the two discs 
corresponding to atrial septum thickness from 
2 to 10 mm. The device has very high flexibility 
and adaptability with unique braiding. 
Six weeks after AFR implantation the patient’s 
clinical status improved (WHO III) with no fluid 
retention on a reduced dose of diuretics. Signifi-Figure 1. Occlutech® atrial flow regulator.
Table 1. Clinical, echocardiographic and hemodynamic parameters before and after atrial flow  
regulator (AFR) implantation.
Before Six weeks after AFR implantation
Functional class (WHO) IVa III
Six minute walking distance [m] 341 420
B-type natriuretic peptide [pg/mL] 250 90
Echocardiography
RV/LV [mm] 59/39 54/46
RVEDvol [ml] 3D echo 265 250
RA area [cm2] 28 25
RV EF [%] 3D echo 23 26
RVSP [mmHg] 105 98
LAESvol index [mL/m2] 23 31
LVEDvol [mL] 88 93
LVEF [%] 52 56
VCI expiration/inspiration [mm] 20/14 17/11
Pericardial effusion No No
Right heart catheterization
Arterial blood pressure (systolic/diastolic) [mmHg] 113/70 100/58
Cardiac index [l/min/m2] 3.19 3.73
Central venous pressure [mmHg] 13 8
RA pressure (systolic/diastolic/mean) [mmHg] 17/10/13 10/7/8
RV pressure (systlic/diastolic/mean) [mmHg] 120/10/62 102/7/50
PA pressure (systlic/diastolic/mean) [mmHg] 128/85/100 100/64/76
Pulmonary capillary wedge pressure [mmHg] 9 11
Diastolic pressure gradient [mmHg] 76 53
Pulmonary vascular resistance [Wood units] 14.6 9.3
SaO2 (PA/mixed/arterial) [%] 72/71/94 70/71/90
Drugs
Furosemide iv [mg] 60 –
Torasemide po [mg] 200 100
Spironolactone iv [mg] 100 50
Chlortalidone po [mg] 50 50
Epoprostenol iv [mg/kg/min] 56 56 
Sildenafil [mg] 60 60
Bosentan [mg] 250 250
3D echo — three-dimensional echocardiography; EF — ejection fraction; iv — intravenous; LAESvol — left atrial end-systolic volume;  
LV — left ventricle; LVEDvol — LV end-diastolic volume; PA — pulmonary artery; po — per os; RA — right atrial; RV — right ventricle;  
RVEDvol — RV end-diastolic volume; RVSP — right ventricular systolic pressure; SaO2 — oxygen saturation; VCI — vena cava inferior;  
WHO — World Health Organization
104 www.cardiologyjournal.org
Cardiology Journal 2019, Vol. 26, No. 1
cant amelioration of RV hemodynamics occurred, 
with decrement in pulmonary vascular resistance, 
increment of cardiac index, and slight reduction in 
SpO2. Echocardiography revealed increase in left 
heart chambers dimensions with decrease in the 
right ones (Table 1).
The present researchers first experience with 
the Occlutech AFR device implementation was 
very promising. It provides a unique therapeutic 
option for decompensated RV failure in end-stage 
PAH patients. Future applications of the AFR 
device may be extended to other heart failure 
populations like severe diastolic left ventricular 
dysfunction with increased left atrial pressure.
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